Lopinavir/ritonavir/rocuronium bromide interactionMyopathy following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1843卷 / 1期

关键词：

D O I：

10.1007/s40278-021-91333-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：231 / 231

相关论文

共 50 条

[41] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2019, 1744 (1) : 111 - 111
[42] NivolumabPsoriasis following an off-label use: case report
Reactions Weekly, 2018, 1717 (1) : 214 - 214
[43] GlibenclamideHypoglycaemia following off-label use: case report
Reactions Weekly, 2021, 1857 (1) : 162 - 162
[44] CatequentinibPneumothorax following off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 158 - 158
[45] TolvaptanHypernatraemia following off-label use: case report
Reactions Weekly, 2019, 1753 (1) : 326 - 326
[46] FelbamateNeutropenia following off-label use: case report
Reactions Weekly, 2020, 1803 (1) : 111 - 111
[47] MethylprednisoloneFungaemia following an off-label use: case report
Reactions Weekly, 2022, 1899 (1) : 243 - 243
[48] SirolimusPneumonia following off-label use: case report
Reactions Weekly, 2020, 1800 (1) : 269 - 269
[49] ClonazepamMisidentification following off-label use: case report
Reactions Weekly, 2022, 1926 (1) : 171 - 171
[50] RituximabAgranulocytosis following off-label use: case report
Reactions Weekly, 2018, 1712 (1) : 482 - 482

← 1 2 3 4 5 →